2022 PSOGI Consensus on HIPEC Regimens for Peritoneal Malignancies: Diffuse Malignant Peritoneal Mesothelioma.
Fiche publication
Date publication
juillet 2023
Journal
Annals of surgical oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MARCHAL Frédéric
Tous les auteurs :
Kepenekian V, Sgarbura O, Marchal F, Villeneuve L, Kusamura S, Deraco M
Lien Pubmed
Résumé
Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive primary peritoneal disease, with recommended treatment, in eligible patients, of a combination of complete cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). As treatment is multimodal, there is a wide heterogeneity of HIPEC protocols precluding clear comparisons. Standardization at an international level is required.
Référence
Ann Surg Oncol. 2023 07 23;: